Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells
Multiple System Atrophy, Parkinsonian Type
Explore 2 assets in Multiple System Atrophy, Parkinsonian Type →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Indonesia University
Modality
Cell therapy
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04876326CT.gov Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple System Atrophy, Parkinsonian Type
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (this asset) | Indonesia University | N/A | D · 30 |
| Carbidopa | Julien Bally | P1/2 | CCC |
| Levodopa | Julien Bally | P1/2 | CCC |
| Verdiperstat | Brigham and Women's Hospital | Early P1 | CC |
| PBR-06 | Brigham and Women's Hospital | Early P1 | CC |
Other indications for Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cerebral Infarction | — | P1/2 | CCC · 50 |
| Cirrhosis Of Liver | — | P1/2 | CCC · 48 |
| Relapsing-Remitting Multiple Sclerosis | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Multiple System Atrophy, Parkinsonian Type. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/allogeneic-human-umbilical-cord-tissue-derived-mesenchymal-stem-cells-multiple-system-atrophy-parkinsonian-type
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →